2,906 results on '"bosentan"'
Search Results
2. Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
3. Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) (POPS or POP02)
4. Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male Subjects
5. Endothelin Receptor Function and Acute Stress (End-Stress)
6. Vascular Dysfunction in Black Individuals: Roles of Nitric Oxide and Endothelin-1 (UMMC_Pilot)
7. Mono vs. Dual Therapy for Pediatric Pulmonary Arterial Hypertension (MoD)
8. The Anti-Atherosclerotic Effects of Endothelin Receptor Antagonist, Bosentan, in Combination with Atorvastatin—An Experimental Study.
9. Simple Determination of Bosentan in Plasma Samples by Reversed-Phase High-Performance Liquid Chromatography.
10. In vivo assessment, formulation, characterization and enhancing pharmacotherapy of encapsulated mini tablets for immediate release Sildenafil citrate and sustained release Bosentan
11. Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care (PTN_POPS)
12. Microfabricated potentiometric sensor based on a carbon nanotube transducer layer for selective Bosentan determination
13. A Study in Healthy Men to Test Whether Bosentan Influences the Amount of BI 425809 in the Blood
14. Drug-Drug Interactions in the Management of Patients With Pulmonary Arterial Hypertension
15. Impact of a Moderate CYP3A4 Inducer (Bosentan) on Lurbinectedin Pharmacokinetics and Safety in Patients with Advanced Solid Tumors: An Open-Label, Two-Way, Crossover, Phase Ib Drug–Drug Interaction Study.
16. Current Management and Future Directions for Pulmonary Arterial Hypertension Associated with Congenital Heart Disease.
17. Safety of Bosentan in Type II Diabetic Patients (BOSRET)
18. Kids Mod PAH trial: A multicenter trial comparing mono-versus duo-therapy for initial treatment of pediatric pulmonary hypertension.
19. ENDOTHELION Study Group: Effect of Bosentan in NAION Patients (ENDOTHELION)
20. The protective effect of bosentan on methotrexate-induced oral mucositis in rats
21. The Anti-Atherosclerotic Effects of Endothelin Receptor Antagonist, Bosentan, in Combination with Atorvastatin—An Experimental Study
22. Solubility of Bosentan in Polyethylene Glycol 400 + Water Mixtures: Experimental and Mathematical Computations
23. Kids Mod PAH trial: A multicenter trial comparing mono‐ versus duo‐therapy for initial treatment of pediatric pulmonary hypertension
24. Evolution of randomized, controlled studies of medical therapy in chronic thromboembolic pulmonary hypertension
25. Pharmacogenomics in Pulmonary Arterial Hypertension
26. Reflex Responses to Intermittent Hypoxia in Humans: Mechanisms and Consequences
27. Study to Evaluate the Effect of Bosentan on the Pharmacokinetics of Lurbinectedin in Patients With Advanced Solid Tumors
28. Desperate Times, Desperate Measures: The Case for RRx-001 in the Treatment of COVID-19
29. Impact of a Moderate CYP3A4 Inducer (Bosentan) on Lurbinectedin Pharmacokinetics and Safety in Patients with Advanced Solid Tumors: An Open-Label, Two-Way, Crossover, Phase Ib Drug–Drug Interaction Study
30. Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of Bosentan
31. Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Participants
32. FUTURE 3 Study Extension (FUTURE 3 Ext)
33. Treatment of nonarteritic anterior ischemic optic neuropathy with an endothelin antagonist: ENDOTHELION (ENDOTHELin antagonist receptor in Ischemic Optic Neuropathy)—a multicentre randomised controlled trial protocol
34. Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension
35. Endothelin-1 Induces Cell Proliferation and Myofibroblast Differentiation through the ET A R/G αq /ERK Signaling Pathway in Human Cardiac Fibroblasts.
36. Cost-Effectiveness Analysis of Macitentan in Comparison With Bosentan in the Treatment of Pulmonary Arterial Hypertension in Iran.
37. Solubility Measurement and Mathematical Modeling for Bosentan in Mixtures of Ethylene Glycol and Water at 293.15–313.15 K.
38. Current Management and Future Directions for Pulmonary Arterial Hypertension Associated with Congenital Heart Disease
39. Call For Tenders For The Supply Of Bosentan 62.5mg Tablets
40. Bosentan Use in Patients With Diabetic Nephropathy
41. VASCULAR AND RENAL IMPACT OF ENDOTHELIN-1 RECEPTOR BLOCKADE IN PATIENTS WITH RESISTANT ARTERIAL HYPERTENSION (ENDOTHELIN-2)
42. Population Pharmacokinetics and Dosage Individualization of Oral Pulmonary Vasodilators in PPHN
43. Drug Therapy and Surgery in Congenital Heart Disease With Pulmonary Hypertension
44. Treatment of nonarteritic anterior ischemic optic neuropathy with an endothelin antagonist: ENDOTHELION (ENDOTHELin antagonist receptor in Ischemic Optic Neuropathy)-a multicentre randomised controlled trial protocol.
45. Monocrotaline-Induced Pulmonary Arterial Hypertension and Bosentan Treatment in Rats: Focus on Plasma and Erythrocyte Parameters.
46. Cardiac-specific knockout and pharmacological inhibition of Endothelin receptor type B lead to cardiac resistance to extreme hypoxia
47. Bosentan‐based, treat‐to‐target therapy in patients with pulmonary arterial hypertension: results from the COMPASS‐3 study
48. Efficacy and safety of switching from bosentan or ambrisentan to macitentan in pulmonary arterial hypertension: A systematic review and meta-analysis
49. Introducing novel hybridization technique for solubility enhancement of Bosentan formulation
50. Endothelin-1 as a novel target for the prevention of metabolic dysfunction with intermittent hypoxia in male participants.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.